Scholarlink

<p>The clinical significance of the long non-coding RNA (lncRNA) RASSF8-AS1 was investigated in non-small cell lung cancer (NSCLC). A comparative analysis of RASSF8-AS1 expression levels was performed in 31 paired samples of tumor tissue and adjacent morphologically normal lung tissue obtained from patients with various histological subtypes of NSCLC. Significant downregulation of RASSF8-AS1 transcript levels was observed in both lung adenocarcinoma (<i>p</i> = 0.0094) and squamous cell carcinoma (<i>p</i> = 0.0005). These findings underscore the potential of RASSF8-AS1 as a molecular marker for distinguishing histological subtypes of NSCLC. Although no significant associations were found between RASSF8-AS1 expression and patient age, tumor stage, or differentiation grade, a statistically significant correlation was identified between high RASSF8-AS1 expression and reduced overall survival specifically in patients with lung adenocarcinoma (hazard ratio, HR = 6.063; <i>p</i> = 0.029). This suggests that lncRNA RASSF8-AS1 may serve as a potential prognostic biomarker in this subgroup. Collectively, the results indicate a possible role for RASSF8-AS1 in NSCLC pathogenesis and support its further evaluation as both a molecular target and a prognostic tool, particularly in the context of personalized therapeutic strategies for lung adenocarcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic and Prognostic Significance of RASSF8-AS1 lncRNA Expression in Non-Small Cell Lung Cancer

  • 期刊论文

  • 发表日期：

    2025年11月1日

查看全文
  • O. V. Kovaleva,
  • V. V. Sinyov,
  • M. A. Rashidova,
  • O. S. Malashenko,
  • V. V. Mochalnikova,
  • N. E. Kushlinskii,
  • A. N. Gratchev

摘要

The clinical significance of the long non-coding RNA (lncRNA) RASSF8-AS1 was investigated in non-small cell lung cancer (NSCLC). A comparative analysis of RASSF8-AS1 expression levels was performed in 31 paired samples of tumor tissue and adjacent morphologically normal lung tissue obtained from patients with various histological subtypes of NSCLC. Significant downregulation of RASSF8-AS1 transcript levels was observed in both lung adenocarcinoma (p = 0.0094) and squamous cell carcinoma (p = 0.0005). These findings underscore the potential of RASSF8-AS1 as a molecular marker for distinguishing histological subtypes of NSCLC. Although no significant associations were found between RASSF8-AS1 expression and patient age, tumor stage, or differentiation grade, a statistically significant correlation was identified between high RASSF8-AS1 expression and reduced overall survival specifically in patients with lung adenocarcinoma (hazard ratio, HR = 6.063; p = 0.029). This suggests that lncRNA RASSF8-AS1 may serve as a potential prognostic biomarker in this subgroup. Collectively, the results indicate a possible role for RASSF8-AS1 in NSCLC pathogenesis and support its further evaluation as both a molecular target and a prognostic tool, particularly in the context of personalized therapeutic strategies for lung adenocarcinoma.